Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | TNNI3 | P19429 | 2/20 | 0.62 |
| ▸ | TNNT2 | P45379 | 2/20 | 0.62 |
| ▸ | TNNC1 | P63316 | 2/20 | 0.62 |
| ▸ | PTPN7 | P35236 | 12/20 | 0.60 |
| ▸ | IKBKB | O14920 | 2/20 | 0.58 |
| ▸ | HSPD1 | P10809 | 3/20 | 0.57 |
| ▸ | HSPE1 | P61604 | 3/20 | 0.57 |
| ▸ | CDC7 | O00311 | 3/20 | 0.56 |
| ▸ | PLK4 | O00444 | 3/20 | 0.56 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9613391 | 0.86 | KDM4D (0.55) | KDM4DMEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL5995022 | 0.85 | KDM4D (1.00) | KDM4DMEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL20272250 | 0.83 | KDM4D (0.82) | KDM4DMEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL9613317 | 0.83 | KDM4D (0.82) | KDM4DMEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL9613299 | 0.82 | KDR (0.55) | KDM4DMEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL6234684 | 0.81 | CHEK1 (0.60) | KDM4DMEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL9613314 | 0.79 | MAPT (0.53) | KDM4DMEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL5992672 | 0.76 | PTPN7 (0.80) | KDM4DMEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL31701626 | 0.76 | MEN1 (0.62) | KDM4DMEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL6238251 | 0.76 | PTPN7 (1.00) | KDM4DMEN1ALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353094-B2 | Substituted quinoxalines as kinase inhibitors | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150274709-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | THE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2015-10-01 | — | — | US | disclosed |
| US-8993758-B2 | Substituted quinoxalines and uses thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130289041-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012071414-A2 | QUINOXALINE COMPOUNDS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274709-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NFKBIA, RELA, MTOR | KDM4D 3685/4885MEN1 3589/4885ALDH1A1 4080/4885 |
| US-20130289041-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NFKBIA, RELA, MTOR | KDM4D 3685/4885MEN1 3589/4885ALDH1A1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.